RxDoctor Payments Data

Alena Costulas, PA

Physician Assistant · Yukon, OKNPI 1851008460

Payments from drug & device makers

$4,692in general payments, 2019–2025

Across 285 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$707
  • AbbVie$641
  • GSK$608
  • Lilly USA, LLC$603
  • Boehringer Ingelheim$438
  • Pfizer$339
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$4,692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,692 in reported general payments places this provider in the 90th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$56,803
Medicare patients
260
Services billed
1,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$47,435
MounjaroTirzepatide16$35,786
JardianceEmpagliflozin22$20,827
FarxigaDapagliflozin Propanediol18$20,188
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$13,952
MyrbetriqMirabegron14$8,782
Albuterol Sulfate HfaAlbuterol Sulfate48$1,765
Celecoxib37$1,413
Omeprazole83$1,398
Atorvastatin Calcium161$1,362
Lubiprostone13$1,254
Gabapentin77$1,169
Montelukast Sodium52$951
Testosterone Cypionate25$840
Rosuvastatin Calcium26$805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$120$47,43540 claims
Lilly USA, LLCMounjaro$603$35,78616 claims
Boehringer IngelheimJardiance$438$20,82722 claims
AstraZenecaFarxiga$707$20,18818 claims
GSKTrelegy Ellipta$608$13,95215 claims
Astellas Pharma US IncMyrbetriq$303$8,78214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →